Modified AAV2 Vectors for Retinal Cell-Specific Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing AAV vectors struggle to efficiently deliver nucleic acid to retinal cells, particularly retinal ganglion cells and retinal pigment epithelium cells, with limited expression levels and specificity, hindering their use in treating retinal conditions.
Innovation Solution
Development of AAV2 vectors with modified capsid polypeptides, such as those with specific amino acid sequences, to enhance infection and expression of nucleic acid in retinal cells, including retinal ganglion cells and retinal pigment epithelium cells, achieving higher expression levels and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type AAV vectors are used for nucleic acid delivery to retinal cells, then the vectors can infect retinal cells, but the expression levels are limited and infection efficiency is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the capsid polypeptide amino acid sequence of AAV2 vectors. Specifically, the invention identifies and modifies key amino acid residues in the capsid structure to alter the vector's tropism and binding affinity, thereby enhancing both infection efficiency and nucleic acid expression levels in retinal cells without changing the fundamental viral structure
Solution Approach 2:
The patent implements local quality by making targeted modifications to specific regions of the capsid polypeptide rather than uniform changes throughout. The invention focuses on modifying particular amino acid sequences in the capsid that are critical for retinal cell recognition and entry, thereby locally enhancing the vector's ability to infect retinal ganglion cells and RPE cells while maintaining overall vector functionality
2Measurement precision
If AAV vectors are used to deliver nucleic acid to retinal cells, then some infection occurs, but the specificity to target cell types (retinal ganglion cells and RPE cells) is limited
Solution Approach 1:
The patent enhances cell type specificity by making localized modifications to the capsid polypeptide sequence that target specific cell surface receptors on retinal ganglion cells and RPE cells. These focused amino acid changes in the capsid structure enable preferential binding to these cell types, achieving high specificity without sacrificing overall infection capability
Solution Approach 2:
The modified capsid polypeptide acts as an intermediary that mediates specific recognition and binding between the AAV vector and retinal cell surface receptors. The engineered amino acid sequences in the capsid serve as molecular mediators that facilitate selective entry into target cells while maintaining efficient infection kinetics
Data Source
AI summary
This document relates to AAV vectors (e.g., AAV2 vectors). For example, AAV vectors (e.g., AAV2 vectors) containing an AAV capsid polypeptide that includes an amino acid sequence set forth in Table 1 (or a variant thereof) or Formula A, such AAV capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV capsid polypeptides, host cells containing and/or expressing such nucleic acid molecules, and methods and materials for making or using such vectors and/or AAV capsid polypeptides are provided.